

REVIEW

Open Access

The clinical case for proton beam therapy

Robert L Foote^{1*}, Scott L Stafford¹, Ivy A Petersen¹, Jose S Pulido², Michelle J Clarke³, Steven E Schild⁹, Yolanda I Garces¹, Kenneth R Olivier¹, Robert C Miller¹, Michael G Haddock¹, Elizabeth Yan¹, Nadia N Laack¹, Carola A S Arndt⁴, Steven J Buskirk¹⁰, Vickie L Miller¹¹, Christopher R Brent¹, Jon J Kruse⁵, Gary A Ezzell⁹, Michael G Herman⁵, Leonard L Gunderson¹¹, Charles Erlichman⁶ and Robert B Diasio^{7,8}

Abstract: Over the past 20 years, several proton beam treatment programs have been implemented throughout the United States. Increasingly, the number of new programs under development is growing. Proton beam therapy has the potential for improving tumor control and survival through dose escalation. It also has potential for reducing harm to normal organs through dose reduction. However, proton beam therapy is more costly than conventional x-ray therapy. This increased cost may be offset by improved function, improved quality of life, and reduced costs related to treating the late effects of therapy. Clinical research opportunities are abundant to determine which patients will gain the most benefit from proton beam therapy. We review the clinical case for proton beam therapy.

Summary sentence: Proton beam therapy is a technically advanced and promising form of radiation therapy.

Keywords: Clinical review, Neoplasms, Proton beam therapy, X-ray therapy

Background

X-rays have been used to treat cancer since 1895. Advances in x-ray therapy over the years include development of linear accelerators that produce high-energy x-rays for deeper penetration. Blocking techniques were developed to contour the beam to conform to the size and shape of the tumor target. Multiple beams and angles are used to adapt the dose to the tumor and to reduce the dose to healthy organs. Advances in imaging have allowed for improved tumor delineation. Four-dimensional imaging allows measurement of motion of both tumor and normal structures during treatment. Changes in tumor size and shape during treatment can be corrected for use of adaptive radiotherapy techniques. Faster and more powerful computers allow for more accurate dose calculations and the delivery of intensity modulated x-ray beams and volumetric arc therapy. Improved patient and organ immobilization devices, along with imaging during treatment to detect patient, organ, and tumor motion (image-guided radiotherapy), enhance the accuracy of treatment delivery.

These advances were accomplished without performing conventional prospective clinical trials. The administration of concurrent radiation-sensitizing chemotherapy and biologically targeted agents has been found to improve both disease control and survival for many cancer patients.


The likelihood of tumor control through radiation therapy is related to the dose delivered to the tumor, and the likelihood of severe organ injury is related to dose to the organ and volume of the organ exposed to radiation [1]. A balance always exists between cure and risk of severe complications. The challenge in using high-energy x-rays to treat cancer is that the x-rays pass through the thickness of the body, depositing an entrance and an exit dose to healthy organs. The dose to healthy organs limits the dose that can be safely administered to the tumor. Radiation oncologists constantly strive to find the optimal balance between a high-enough dose to prevent cancer recurrence and a low-enough dose to avoid injury to healthy organs.

Proton beam therapy offers an option for obtaining that balance. Hospital- or clinic-based proton beam facilities have been in existence since 1990. Currently, 11 proton beam facilities are in operation in the United States (Figure 1) and 26 are operational in 13 other countries (Russia, Switzerland, Sweden, England,

* Correspondence: foote.robert@mayo.edu

¹Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota

Full list of author information is available at the end of the article



France, South Africa, Canada, Germany, Japan, Italy, China, South Korea, and Poland) (Figure 2). Eighteen proton beam facilities are under construction in Switzerland, Czech Republic, Austria, Italy, China, Germany, Taiwan, Russia, Slovak Republic, Sweden, and the United States.

Protons are positively charged subatomic particles that are massive compared with x-rays. The biologic effects of protons and x-rays on cells are similar since both are sparsely ionizing with a relatively small linear energy transfer. However, the way protons interact with matter provides advantages compared with x-rays. As protons enter the body, they deposit a very low entrance dose. The depth of proton penetration is dependent on kinetic energy and, hence, the higher the energy, the deeper is the penetration. When the proton arrives at its target, it delivers the dose and stops, thereby eliminating an exit dose. This physical advantage serves to lower the dose to healthy organs both superficial and deep to the tumor, thus reducing the risk of injury. It also allows administration of a higher dose to the tumor, potentially reducing the recurrence rate without increasing the complication rate and leading to better organ function and quality of life. This result can lead to an avoidance of costs associated with treating recurrent tumors and damaged organs. This effect is particularly important in young children with a high likelihood of cure who are strongly susceptible to the long-term effects of x-ray therapy and in patients with cancers located adjacent to critical healthy organs, such as the eye, brain, brainstem, spinal cord, lung, heart, liver, bowel, and kidneys.

Clinical review

Ocular (choroidal) melanoma

Treatment options for patients with ocular melanoma include 1) enucleation, 2) suturing of a radioactive plaque to the eye overlying the melanoma, and 3) proton beam therapy. No differences in survival between treatments have been reported in prospective clinical trials [2,3]. Advantages of the radioactive plaque and proton beam therapy are preservation of the eye and vision. In a phase 3 study performed to compare the radioactive plaque with helium ion therapy (helium ions contain 2 protons), there were fewer recurrences of the melanoma in those patients treated with helium ions (0% vs 13.3%) [3]. The proportion of patients who required enucleation because of melanoma recurrence or complications was less when they were treated with helium ion therapy (9.3% vs 17.3%). The proportion of eyes with visual acuity greater than 20/40 was the same with both treatments (21%-23%).

The Mayo Clinic experience with radioactive plaques has been reported [4]. The recurrence rate is 8%; the enucleation rate is 8%. The proportion of patients with visual acuity greater than 20/40 is 22%. Several large series of patients treated with proton beam therapy have been reported, confirming low recurrence rates (3%-4%) and low enucleation rates (9.4%-11%), with visual acuity greater than 20/40 in 44.8% [5-9]. Of these series, the larger ones included 1,406 patients treated in France [8]; 2,435 patients in Switzerland [9]; and 2,815 patients in Boston, Massachusetts [7]. A phase 3 study conducted by the Massachusetts Eye and Ear Infirmary compared 2 different dose levels of proton beam therapy, 50 Gy and 70 Gy [10]. No differences were noted in outcome, with




Figure 2 Proton beam treatment facilities that are operational or under construction outside the United States.

recurrence rates of 2% to 3% and enucleation rates of 4% to 5%.

Proton beam therapy has a number of advantages over radioactive plaques, including 1) localization requires 1 or no surgery, depending on technique, 2) no hospital stay is needed, yet treatment is still completed in 5 calendar days, 3) more patients are eligible for proton beam therapy than radioactive plaque therapy because of the ability to treat larger tumor sizes and tumors surrounding the optic nerve, and 4) medical staff have no radiation exposure.

Skull base chordoma

Skull base chordomas are rare tumors that are difficult to completely remove surgically. Doses of radiation therapy are limited because of the adjacent brain, brainstem, cranial nerves, and spinal cord structures. At Mayo Clinic, with a combination of aggressive surgical debulking, 3-dimensional (3-D) conformal x-ray therapy, and Gamma Knife radiosurgery, the 5-year tumor control rate was 32% in 25 patients [11]. At the Paul Scherrer Institute in Switzerland, with a combination of surgical debulking and scanning proton beam therapy, the 5-year

tumor control rate was 81% in 42 patients [12]. The incidence of symptomatic temporal lobe injury at Mayo Clinic was 10% vs 6% with scanning proton beam therapy at the Paul Scherrer Institute [11,12]. At the Harvard Cyclotron Laboratory, 290 patients with skull base chordomas were treated with scattered proton beams [13]. The 5-year tumor control rate was 73%, with an 8% incidence of temporal lobe injury. It appears from these data that proton beam therapy is more effective than x-ray therapy in producing a greater probability of long-term tumor control without increasing the risk of temporal lobe injury.

Lung cancer

Standard treatment for locally advanced, inoperable non-small cell lung cancer includes a combination of chemotherapy and x-ray therapy. Median survival is about 17 months, with 50% of the patients having severe toxicity related to treatment (60 Gy of x-ray therapy) [14,15]. Results of phase 3 studies using combined x-ray therapy (60–64 Gy) and chemotherapy report long-term survivors (3–5 years) in 15% to 18% with a 40% to 80% recurrence rate and 48% to 53% of patients having serious or life-

threatening toxicity (ie, esophagitis and pneumonitis) [14,15]. The North Central Cancer Treatment Group (including Mayo Clinic) performed a phase 1 dose-escalating trial and found that, by increasing the x-ray therapy dose to 74 Gy, the median overall survival was favorable at 40 months and the recurrence rate was reduced to 15%, but the serious, life-threatening toxicity continued to be high at 54% [16]. The MD Anderson Cancer Center performed a phase 2 dose-escalating trial using proton beam therapy and confirmed that 74 Gy resulted in a favorable median overall survival (29.4 months) and decreased the recurrence rate to 20% [17]. In addition, the incidence of serious toxicity was reduced with proton beam therapy and included dermatitis (11%), esophagitis (11%), and pneumonitis (2%). These results suggest that there is an opportunity to take advantage of dose escalation with proton beam therapy to prolong survival; lower the recurrence rate; decrease the risk of serious, life-threatening toxicity; and intensify chemotherapy. A recently completed phase 3 study comparing a modest dose increase from 60 Gy to 74 Gy of x-ray therapy failed to demonstrate improved survival with 74 Gy [18]. The assumed reason for this lack of benefit was death due to higher doses of x-ray therapy affecting the heart and lungs adversely [19]. This outcome suggests that further dose escalation with x-rays will not be feasible. Massachusetts General Hospital and MD Anderson Cancer Center are nearing completion of a phase 3 clinical trial comparing x-rays to protons in the treatment of locally advanced non-small cell lung cancer.

Hodgkin lymphoma in children, adolescents, and young adults

Hodgkin lymphoma (HL) is a curable hematogenous malignancy that affects primarily children and young adults and in which consolidation x-ray therapy is often used after chemotherapy for treatment of initially involved lymph node groups. Survivors of HL have an excessive amount of secondary malignancy (SM), with a 15-year risk of about 15%. Although x-ray therapy may improve outcomes in HL, it may increase the risk of SM, particularly breast, lung, and thyroid cancers and hematogenous cancers. The risk of radiation-induced cancers is proportional to the dose delivered. Using a proton beam treatment planning system, we compared the distribution of proton dose to x-ray dose in patients with HL treated with x-ray therapy at Mayo Clinic. We found that the integral dose of exposure radiation to the patient was reduced by at least 50% with the use of scattered or scanned proton beams compared with 3-D or intensity modulated x-ray beams. This reduction predicts that the risk of radiation-induced cancers would be reduced by at least 50%.

A study from Massachusetts General Hospital of 1,450 patients treated with proton beam therapy at the

Harvard Cyclotron Laboratory appears to support this conclusion [20]. A subset of the patients (n=503) was matched to similar patients identified in the Surveillance Epidemiology and End Results cancer registry who were treated with x-ray therapy (n=1,591). SM was reported in 12.8% of the patients treated with x-ray therapy compared with 6.4% in patients treated with proton beam therapy (adjusted hazard ratio, 2.73; 95% confidence interval, 1.87-3.98; $P<.0001$). These data substantiate what we would have predicted by evaluating the x-ray vs proton beam dosimetry. Other investigators have similarly concluded that proton beam therapy may reduce the risk of SM by up to 50% in comparison with x-ray therapy [21].

Similarly, cardiac irradiation during HL x-ray therapy has been associated with an increased risk of coronary artery disease and valvular dysfunction [22,23]. Therefore, a substantial reduction in health care costs, lost productivity, morbidity, death, and human suffering in HL survivors could be realized with the use of proton beam therapy.

Esophageal and gastroesophageal junction cancers

The current standard of care for locally advanced esophageal cancer is concurrent chemotherapy and x-ray therapy with or without surgical resection. The 5-year overall survival rate is 20% to 30%. The incidence of treatment-related toxicity that is severe or worse is 33% [24]. Irradiation of the heart has been shown to increase the risk of a myocardial perfusion abnormality [25]. A recent review of the Mayo Clinic experience found that the incidence of non-cancer-related deaths within the first year after treatment was 8% following chemotherapy and x-ray therapy without surgery, 33% following preoperative chemotherapy and x-ray therapy, and 20% following postoperative chemotherapy and radiation therapy. The majority of these deaths were due to cardiopulmonary toxicity. The risk of cardiac toxicity due to x-ray therapy is dependent on the dose delivered and the volume of heart exposed to radiation [1]. Through comparative treatment planning analysis of x-ray and proton beams, we found that the dose delivered to one-third the volume of the heart was reduced from 75% of the dose prescribed to the tumor with conventional x-ray therapy to 58% with intensity modulated x-ray therapy and to just 9% with proton beam therapy. This finding suggests that cardiac-related morbidity and death could potentially be reduced by using proton beam therapy to treat esophageal cancer.

Pediatric cancers

Great advances have been made in the treatment of pediatric cancers. Currently, 85% of pediatric cancer patients are cured, although 65% of long-term survivors

have chronic health conditions, with death from a SM or other treatment-related event occurring in 20% [26-32]. Despite the increased use of chemotherapy in the management of pediatric cancers, x-ray therapy has an important role in the treatment of approximately 50% of children with cancer, particularly children with brain tumors. However, although x-ray therapy is effective in many children, their quality of life is frequently compromised by late effects of x-ray therapy.

In pediatric practice, the relatively large volume of the body exposed to low doses of x-ray therapy is frequently clinically relevant in relation to long-term effects. Treatment complications include neurocognitive deficits, hearing loss, pituitary dysfunction, hypothyroidism, cardiac dysfunction, pulmonary disease, diminished vertebral body growth, scoliosis, gastrointestinal tract dysfunction, infertility, and SM. The marked reduction in dose to the body and healthy organs associated with proton beam therapy may be used to reduce the extent of the harmful low-dose x-ray effect and thus may be clinically beneficial in pediatric radiation oncology practice.

Medulloblastoma is the second most common pediatric brain tumor. This tumor classically develops in the posterior fossa with frequent metastases along the craniospinal axis, and thus craniospinal axis x-ray therapy is a vital component of treatment. Once considered incurable, the 5-year overall survival rate is now in excess of 65% following treatment with a combination of surgery, x-ray therapy, and chemotherapy. This rate raises concerns regarding long-term, treatment-associated adverse effects.

Of utmost concern are the neuropsychological effects of x-ray therapy to the central nervous system, including impaired neurocognitive development and behavioral disorders. These effects are dose and volume dependent. There is evidence—from whole-brain irradiation for leukemia—of a dose–response effect on long-term neuropsychological effects [33]. In a recent study of children treated for medulloblastoma, Grill et al. [34] showed a significant correlation between full-scale IQ scores and x-ray dose, with mean scores of 84.5, 76.9, and 63.7 for 0, 25, and 35 Gy, respectively. A dose–response curve relating the probability of neuropsychological sequelae to brain dose has been derived from an analysis of the medical literature [33]. Mulhern et al. [35] prospectively examined the neuropsychological functioning of children with medulloblastoma treated in the POG 8631/CCG 923 study. They found that children treated with 23.4 Gy craniospinal axis x-ray therapy had less neuropsychological toxicity than those treated with 36 Gy.

Long-term effects from x-ray therapy for pediatric cancers include hypoplasia of soft tissue and bone. In children treated with abdominal x-ray therapy for Wilms tumor, 19.6% were reported to have clinically significant

long-term orthopedic deficits [36]. There is evidence that the severity of these effects is dose related [37]. Other long-term effects include hearing loss; primary hypothyroidism; thyroid cancer; cardiomyopathy, especially when x-ray therapy is combined with anthracycline chemotherapy; cardiac valvular disease; early onset coronary artery disease; infertility related to pelvic x-ray therapy; and secondary osteosarcoma related to x-ray therapy for Ewing sarcoma, retinoblastoma, or medulloblastoma.

The goal of clinicians is not only to eradicate the primary tumor, but also to minimize the risk of radiation-induced cancers over the lifetime of these children. The observation that many of the late effects of x-ray therapy appear to be dose dependent provides the rationale for proton beam therapy reducing some of the effects that result from exposing structures outside the tumor target volume to radiation.

Comparison of treatment plans using proton, conventional x-ray, or intensity modulated x-ray beams has showed improved dose distributions with proton beams, with modeling estimating a 2-fold reduction or more in risk of a radiation-induced cancer for a child with rhabdomyosarcoma and an 8- to 15-fold decrease for a child with medulloblastoma (due to larger treatment volume) [38]. A study comparing the risk of radiation-induced cancer following spinal irradiation for childhood medulloblastoma after various radiation delivery techniques found the highest lifetime risk of SM with intensity modulated x-ray therapy (30%) and the lowest risk with intensity modulated proton therapy (4%) (Table 1) [39]. These studies underscore the concern with using x-ray therapy in the treatment of pediatric cancers.

Table 2 illustrates a comparison of 3 radiation therapy treatment delivery techniques for a child with medulloblastoma [40]. The substantial sparing of healthy tissue is apparent in proton beam therapy of the posterior fossa and spinal axis.

A recent publication from Sweden projected decreased health care expenses using proton beam therapy in the treatment of pediatric medulloblastoma [41]. The initial cost of proton beam therapy (€10,217.90) was approximately 2.5 times the initial cost of x-ray therapy (€4,239.10). However, the cost of treating adverse events related to x-ray therapy (€33,857.10) was 8 times greater than the cost of treating adverse events related to proton beam therapy (€4,231.80). Considering both initial cost of treatment and the cost of treating adverse events related to the treatment, x-ray therapy was 2.6 times more costly than proton beam therapy (€38,096.20 vs €14,449.70). The additional costs related to treating adverse events associated with x-ray therapy were due to IQ loss, hearing loss, growth hormone deficiency, hypothyroidism, osteoporosis, and SM.

Table 1 Estimated risk of radiation-induced cancer by radiation delivery technique following spinal irradiation for childhood medulloblastoma

Radiation delivery technique	Risk of radiation-induced cancer, %
Intensity modulated x-ray beam	30
Electron beam	21
Conventional x-ray beam	20
Intensity modulated electron beam	15
Intensity modulated proton beam	4

Data from Mu et al. [39].

Dosimetric and clinical studies have demonstrated the benefits of proton beam therapy compared with x-ray therapy in reducing dose and harm to healthy organs in children with retinoblastoma, medulloblastoma, pelvic soft tissue sarcoma, bone sarcoma, and orbital rhabdomyosarcoma [42,43].

Breast cancer

The meta-analysis of the Early Breast Cancer Trialists' Collaborative Group demonstrated improved 5-year tumor control and improved 15-year breast cancer and overall mortality rates with the use of adjuvant x-ray therapy [44]. The therapy was used in the clinical setting of breast-conserving and postmastectomy treatment. However, x-ray therapy was associated with an excess of SM (lung cancer relative risk [RR], 1.61 [$P=.0007$]; esophageal cancer RR, 2.06 [$P=.05$]; leukemia RR, 1.71 [$P=.04$]; soft tissue sarcoma RR, 2.34 [$P=.03$]; contralateral breast cancer RR, 1.18 [$P=.002$]) and non-breast cancer deaths (any non-breast cancer RR, 1.12 [$P=.001$]; pulmonary embolism RR, 1.94 [$P=.02$]; heart disease RR, 1.27 [$P=.0001$]; lung cancer RR, 1.78 [$P=.0004$]; and esophageal cancer RR, 2.4 [$P=.04$]). The non-breast cancer deaths reduce the efficacy of x-ray therapy by 20%. In patients with positive axillary lymph nodes undergoing postmastectomy chest wall and nodal x-ray therapy, 30% die of noncancer-related deaths. If the morbidity and death due to SM and cardiopulmonary disease could be reduced or eliminated, the overall survival advantage for women treated with x-ray therapy would be further

Table 2 Dose to cochlea and heart by radiation delivery technique following craniospinal irradiation for childhood medulloblastoma

Radiation delivery technique	Dose to 90% of the cochlea, %	Dose to 50% of the heart volume, %
Conventional x-ray beam	101.2	72.2
Intensity modulated x-ray beam	33.4	29.5
Proton beam	2.4	0.5

Data from St Clair et al. [40].

improved, along with reduction in human suffering and health care costs. The risk of cardiotoxicity is increasingly important in light of the cardiotoxicity associated with anthracycline and, more recently, trastuzumab treatment, which are mainstays in modern adjuvant medical therapy for breast cancer.

We developed 3 treatment plans for a cohort of women with left-sided stage I breast cancer who were undergoing breast-conserving therapy at Mayo Clinic with lumpectomy and breast irradiation. The first plan used conventional x-ray therapy to the entire breast, with an electron boost to the tumor cavity; the second used passively scattered proton beams; and the third used actively scanned proton beams. Compared with the x-ray and electron boost plan, the 2 proton beam plans substantially reduced all measures of lung dose. For example, the mean total lung dose was reduced by 71% using the passively scattered beams and by 81% using the actively scanned beams. Both proton beam plans eliminated the dose to the contralateral lung. The 2 proton beam plans also reduced all measures of dose to the heart. For example, the mean total heart dose was reduced by 75% with the passively scattered beams and by 99% with the actively scanned beams. The mean dose to the contralateral breast was reduced with the proton beam plans compared with the x-ray and electron beam plan—by 88% using the passively scattered beams and by 96% using the actively scanned beams. In addition, the 2 proton beam plans reduced the mean dose to the entire body by 37% for the passively scattered proton beams and by 54% for the actively scanned proton beams.

A similar dosimetric study of women undergoing post-mastectomy chest wall and regional lymph node irradiation at Mayo Clinic revealed similar advantages to protons compared with x-rays. Other investigators have confirmed these findings [45-49]. Lundkvist et al. [50] have demonstrated that proton beam therapy is cost-effective in women with left-sided breast cancer and risk factors for cardiac disease, on the basis of a lower cost per quality-adjusted life-year. Cost-effectiveness will be further improved when investigators also include the cost reductions associated with a reduced incidence of radiation-induced malignancy and pulmonary disease. It is hypothesized that proton beam therapy will be most cost-effective in young women with left-sided breast cancer; in women with a long life expectancy; and in women with risk factors for cardiopulmonary disease, a desire to avoid mastectomy, and indications for postmastectomy chest wall and nodal irradiation.

Current clinical trials are evaluating the safety, efficacy, and cosmetic outcome of partial breast irradiation compared with whole breast irradiation. Should these trials document a meaningful clinical advantage to partial breast irradiation, Taghian et al. [48], Kozak et al.

[49,51], and Bush et al. [52,53] have demonstrated that partial breast irradiation using proton beam therapy is safe, effective, and technically feasible; provides excellent tumor coverage; and improves healthy tissue (heart and lung) sparing, including nontarget breast tissue, when compared with partial breast irradiation using conventional x-rays and electron beams. In addition, it is less expensive than intracavitary and interstitial brachytherapy.

Prostate cancer

The treatment of prostate cancer with proton beam therapy is controversial. Current treatment options include prostatectomy, brachytherapy, and intensity modulated x-ray therapy, all of which are less costly than proton beam therapy.

Prospectively randomized clinical trials have demonstrated that higher doses of x-ray therapy result in improved survival and lower doses to the rectum and bladder result in lower risks of complications. A phase 3 study funded by the NHS Trust randomly assigned 225 men with prostate cancer to 2-dimensional (2-D) or 3-D conformal x-ray therapy [54]. The results of this study proved the principle that reducing the radiation dose to the rectum and bladder by using 3-D conformal techniques reduces the incidence of \geq grade 2 bowel toxicity (from 18% with 2-D to 8% with 3-D) and bladder toxicity (from 23% with 2-D to 20% with 3-D). A phase 3 dose-escalation study conducted by MD Anderson Cancer Center randomly assigned 301 patients to 70 Gy using 2-D x-ray therapy vs 78 Gy using 3-D conformal x-ray therapy [55,56]. This study proved that a higher dose of x-ray therapy results in fewer recurrences (79% 5-year freedom from biochemical failure with 78 Gy vs 69% with 70 Gy). The \geq grade 2 bowel and bladder toxicity was 14% (bowel) and 20% (bladder) for 2-D compared with 21% (bowel) and 9% (bladder) for 3-D x-rays.

The reduced recurrence rate using a higher dose has been confirmed by another phase 3 clinical trial conducted by the Netherlands Cancer Institute, in which 664 men were randomly assigned to 68 Gy vs 78 Gy using 3-D conformal x-ray therapy [57]. The 5-year freedom from biochemical failure was increased from 53% with 68 Gy to 66% with 78 Gy. The \geq grade 2 bowel toxicity was 27% with 68 Gy and 32% with 78 Gy; the \geq grade 2 bladder toxicity was 41% with 68 Gy and 39% with 78 Gy. Intensity modulated x-ray therapy has been administered to a dose as high as 81 Gy in 561 men with prostate cancer at Memorial Sloan-Kettering Cancer Center, with \geq grade 2 bowel toxicity of just 1.6% and \geq grade 2 bladder toxicity of 12% [58]. Loma Linda University Medical Center has reported the results of treating 1,255 men with prostate cancer to 74 Gy using proton beam therapy [59]. The 5-year freedom from

biochemical failure was 75%, with 3.5% \geq grade 2 bowel toxicity and 5.4% \geq grade 2 bladder toxicity.

Finally, Massachusetts General Hospital and Loma Linda University Medical Center conducted a phase 3 dose-escalation study in 393 patients with prostate cancer using a combination of x-rays with a proton beam boost to the prostate gland [60]. Patients were randomly assigned to 70.2 Gy or 79.2 Gy. There was a significant improvement in the 5-year freedom from biochemical failure rate in men randomly assigned to 79.2 Gy (80%) compared with those randomly assigned to 70.2 Gy (61%) ($P < .0001$). This improvement in recurrence rate with higher dose was obtained without significantly increasing the risk of \geq grade 2 bowel toxicity (9% with 70.2 Gy vs 18% with 79.2 Gy) or bladder toxicity (20% with 70.2 Gy vs 21% with 79.2 Gy). Only 2% of patients in both treatment arms had late severe (\geq grade 3) genitourinary toxicity and 1% of patients in the high-dose arm had late \geq grade 3 gastrointestinal tract toxicity [61]. A cost-effectiveness study suggested that proton beam therapy may be cost-effective in young men with intermediate-risk prostate cancer who have longer life expectancy [62].

In summary, direct evidence shows that the higher the dose of radiation administered, the lower the risk of prostate cancer recurrence. Direct evidence also shows that lower doses to the rectum and bladder are associated with a lower risk of complications. Indirect evidence shows that with highly conformal techniques (intensity modulated x-ray therapy or proton beam therapy), the dose can be further escalated without increasing the risk of bowel or bladder toxicity and, in fact, with a lower risk of harm than with conventional 2-D and 3-D x-ray therapies. A phase 3 study comparing high-dose intensity modulated x-ray therapy with proton beam therapy was recently opened to patient accrual.

One way of drastically reducing the cost of proton beam therapy compared with intensity modulated x-ray therapy and bringing it more in line with prostatectomy and brachytherapy is to reduce the number of treatments from 40 to 45 administered over 8 or 9 weeks to 5 treatments administered in 1 week [63]. This regimen would be far more convenient for patients and reduce their time off work and their out-of-pocket expenses. Clinical trials evaluating the safety and efficacy of hypofractionated proton beam therapy should be designed and conducted.

Head and neck cancer

Evidence exists that patients with head and neck cancer may benefit from proton beam therapy by increasing the dose to the cancer to reduce recurrence risk and by reducing the dose to the salivary glands, mandible, and maxilla to lower the risk for dry mouth, dental caries, dental extractions, and osteoradionecrosis [64-67]. The

risk of osteoradionecrosis has been shown to be associated with the total dose and the dose per treatment received by the mandible, with a 0% risk for less than 54 Gy at 1.8 Gy per treatment and a 9.8% risk for 54 Gy or greater at 1.8 Gy per treatment [68]. We evaluated a cohort of consecutive patients at Mayo Clinic undergoing postoperative adjuvant x-ray therapy for tongue cancer. We planned that each patient would receive intensity modulated x-rays and actively scanned proton beams. All measures of mandibular dose were significantly reduced in the patients receiving actively scanned proton beams. For example, the mean volume of the mandible receiving 54 Gy with intensity modulated x-ray beams was 61% (range, 37%-90%) compared with 26% (range, 6%-51%) with actively scanned proton beams ($P=.002$). Furthermore, the mean parotid dose was reduced from 33.1 Gy (range, 24.2-44.1 Gy) with intensity modulated x-ray beams to 19.3 Gy (range, 9.6-32.6 Gy) with actively scanned proton beams ($P=.002$), thereby significantly reducing the risk of xerostomia [69].

Other cancers

Potential advantages of proton beam therapy exist for rectal and anal cancers (lower dose to bowel, bladder, and hips); gastric, pancreatic, and hepatobiliary cancers (lower dose to liver, small bowel, heart, lungs, kidneys, and spinal cord); and bone and soft tissue sarcomas. Improved hematologic tolerance may allow dose intensification of chemotherapy given concurrently with proton beam therapy for thoracic, gastrointestinal tract, and other cancers [17].

Take home points

Mayo Clinic is a national provider of health care with clinics and hospitals in Arizona, Florida, Georgia, Iowa, Minnesota, and Wisconsin caring for more than 13,000 new cancer patients annually. The most common types of cancer treated with radiation therapy at Mayo Clinic are breast cancer (15%), lung cancer (12%), prostate cancer (11%), gastrointestinal tract cancers (10%), and head and neck cancer (5%). In 2002, the Department of Radiation Oncology participated in a departmental exercise to review its status and determine its future direction. As a result of this exercise, the implementation of a charged particle therapy program became a top priority.

There is always a dilemma for large medical practices on the timing for the implementation of new technologies. *Health technology assessment* is the systematic evaluation of properties, effects, or other impacts of health technology. The main purpose of a health technology assessment is to inform decision making for policy decisions related to technology in health care. The assessment may address the direct and intended consequences of technologies, as well as their indirect and

unintended consequences. Historically, the emphasis has been on technology assessment among hospitals, health systems, and health plans. The most common form of technology assessment has focused around pharmaceuticals through pharmacy and therapeutics committees [70]. However, in recent years the interest has been increasing in technology assessment around devices and procedures. For example, 64-slice computed tomography, positron emission tomography, da Vinci robots, health information technology systems, and telemonitoring programs have undergone technology assessments commonly. Typically, the goal of these committees is to weigh the benefits and costs and conduct analyses of return on investment of new technologies. This evaluation also allows health systems to identify priorities for investment.

We recognize the need to generate, evaluate, integrate, and manage knowledge and information related to proton beam therapy. To transform the cancer care delivery process and to be trusted and affordable through the reduction of harm and cost to patients and society, health care providers will need to define which patients benefit the most from proton beam therapy and to define outcomes (tumor control, overall survival, patient-reported function and quality of life, and cost-effectiveness) prospectively in controlled clinical trials and registries.

Abbreviations

HL: Hodgkin lymphoma; RR: Relative risk; SM: Secondary malignancy; 3-D: 3-dimensional; 2-D: 2-dimensional.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All of the authors participated in the writing, reviewing, and editing of the manuscript. All authors read and approved the final manuscript.

Author details

¹Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ²Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ³Department of Neurologic Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ⁴Divisions of Pediatric Hematology and Oncology and Orthopedic Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ⁵Division of Medical Physics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ⁶Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ⁷Division of Oncology Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Minnesota. ⁸Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. ⁹Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, Arizona. ¹⁰Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida. ¹¹Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona.

Received: 30 September 2012 Accepted: 17 October 2012

Published: 22 October 2012

References

1. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al: Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys* 2010, **76**(3 Suppl):S3-S9.

2. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al: Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings: COMS Report No. 18. *Arch Ophthalmol* 2001, **119**(7):969–982.
3. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T: Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial. *Ophthalmology* 1993, **100**(10):1547–1554.
4. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM: Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. *Int J Radiat Oncol Biol Phys* 2005, **63**(1):101–108.
5. Rajendran RR, Weinberg V, Daftari IK, Castro JR, Quivey JM, Char DH, et al: Decreased incidence of neovascular glaucoma by sparing anterior structures of the eye for proton beam therapy of ocular melanoma [abstract]. *Int J Radiat Oncol Biol Phys* 2004, **60**(1):S311–S312.
6. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD: Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. *Int J Radiat Oncol Biol Phys* 2005, **62**(5):1405–1411.
7. Munzenrider JE: Uveal melanomas: conservation treatment. *Hematol Oncol Clin North Am* 2001, **15**(2):389–402.
8. Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, et al: Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). *Int J Radiat Oncol Biol Phys* 2006, **65**(3):780–787. Epub 2006 May 2.
9. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, et al: Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. *Int J Radiat Oncol Biol Phys* 2001, **51**(1):138–147.
10. Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, et al: A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. *Arch Ophthalmol* 2000, **118**(6):773–778.
11. Krishnan S, Foote RL, Brown PD, Pollock BE, Link MJ, Garces YL: Radiosurgery for cranial base chordomas and chondrosarcomas. *Neurosurgery* 2005, **56**(4):777–784. discussion 777–84.
12. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. *Int J Radiat Oncol Biol Phys* 2009, **75**(4):1111–1118. Epub 2009 Apr 20.
13. Munzenrider JE, Liebsch NJ: Proton therapy for tumors of the skull base. *Strahlenther Onkol* 1999, **175**(Suppl 2):57–63.
14. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011, **103**(19):1452–1460. Epub 2011 Sep 8. Erratum in: *J Natl Cancer Inst*. 2012 Jan 4;104(1):79.
15. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. *Lung Cancer* 2004, **46**(1):87–98.
16. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, et al: Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006, **65**(4):1106–1111. Epub 2006 May 26.
17. Sejal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, et al: Early Findings on Toxicity of Proton Beam Therapy with Concurrent Chemotherapy in Nonsmall Cell Lung Cancer. *Cancer* 2011, **117**:3004–3013.
18. Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild SE, et al: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 [abstract]. Miami Beach, FL: 53rd Annual Meeting of the American Society for Radiation Oncology; 2011.
19. Cox JD: Are the results of RTOG 0617 mysterious? *Int J Radiat Oncol Biol Phys* 2012, **82**(3):1042–1044.
20. Chung CS, Keating N, Yock T, Tarbell N: Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy [abstract]. *Int J Radiat Oncol Biol Phys* 2008, **72**(1):S8.
21. Schneider U, Lomax A, Pehler P, Besserer J, Ross D, Lombriser N, et al: The impact of IMRT and proton radiotherapy on secondary cancer incidence. *Strahlenther Onkol* 2006, **182**(11):647–652.
22. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al: Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. *J Clin Oncol* 2007, **25**(1):43–49. Erratum in: *J Clin Oncol*. 2007 Apr 20;25[12]:1635.
23. Hull MC, Morris CG, Pepine CJ, Mendenhall NP: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. *JAMA* 2003, **290**(21):2831–2837.
24. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al: Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). *JAMA* 1999, **281**(17):1623–1627.
25. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, et al: The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. *J Nucl Med* 2006, **47**(11):1756–1762.
26. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al: Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. *J Clin Oncol* 2009, **27**(14):2328–2338. Epub 2009 Mar 30.
27. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al: Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. *J Natl Cancer Inst* 2010, **102**(16):1272–1283. Epub 2010 Jul 23.
28. Aksnes LH, Bauer HC, Dahl AA, Fossa SD, Hjorth L, Jebsen N, et al: Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. *Pediatr Blood Cancer* 2009, **53**(1):84–89.
29. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, et al: Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. *Pediatr Blood Cancer* 2005, **44**(7):643–653.
30. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al: Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2010, **102**(14):1083–1095. Epub 2010 Jul 15.
31. Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C: Second cancers in patients with the Ewing sarcoma family of tumours. *Eur J Cancer* 2008, **44**(7):983–991. Epub 2008 Mar 18.
32. Armstrong GT, Stovall M, Robison LL: Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. *Radiat Res* 2010, **174**(6):840–850. Epub 2010 Sep 17.
33. Miralbell R, Lomax A, Bortfeld T, Rouzaud MM, Carrie C: Potential role of proton therapy in the treatment of pediatric ependyoblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. *Int J Radiat Oncol Biol Phys* 1997, **38**(3):477–484.
34. Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, et al: Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. *Int J Radiat Oncol Biol Phys* 1999, **45**(1):137–145.
35. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. *J Clin Oncol* 1998, **16**(5):1723–1728.
36. Taylor RE, United Kingdom Children's Cancer Study Group: Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. *Clin Oncol (R Coll Radiol)* 1997, **9**(6):381–384.
37. Willman KY, Cox RS, Donaldson SS: Radiation induced height impairment in pediatric Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1994, **28**(1):85–92.
38. Miralbell R, Lomax A, Cella L, Schneider U: Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. *Int J Radiat Oncol Biol Phys* 2002, **54**(3):824–829.

39. Mu X, Bjork-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al: Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? a comparative treatment planning study. *Acta Oncol* 2005, **44**(6):554–562.
40. St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, et al: Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. *Int J Radiat Oncol Biol Phys* 2004, **58**(3):727–734.
41. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B: Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. *Cancer* 2005, **103**(4):793–801.
42. Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, et al: Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? *Int J Radiat Oncol Biol Phys* 2005, **63**(2):362–372.
43. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N: Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. *Int J Radiat Oncol Biol Phys* 2005, **63**(4):1161–1168. Epub 2005 Jun 13.
44. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005, **366**(9503):2087–2106.
45. Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R: Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. *Int J Radiat Oncol Biol Phys* 2003, **55**(3):785–792.
46. Johansson J, Isacson U, Lindman H, Montelius A, Glimelius B: Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. *Radiother Oncol* 2002, **65**(2):89–98.
47. Weber DC, Ares C, Lomax AJ, Kurtz JM: Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview. *Radiat Oncol* 2006, **1**:22.
48. Taghian AG, Kozak KR, Katz A, Adams J, Lu HM, Powell SN, et al: Accelerated partial breast irradiation using proton beams: initial dosimetric experience. *Int J Radiat Oncol Biol Phys* 2006, **65**(5):1404–1410. Epub 2006 May 26.
49. Kozak KR, Katz A, Adams J, Crowley EM, Nyamwanda JA, Feng JK, et al: Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. *Int J Radiat Oncol Biol Phys* 2006, **65**(5):1572–1578.
50. Lundkvist J, Ekman M, Ericsson SR, Isacson U, Jonsson B, Glimelius B: Economic evaluation of proton radiation therapy in the treatment of breast cancer. *Radiother Oncol* 2005, **75**(2):179–185.
51. Kozak KR, Smith BL, Adams J, Kornmehl E, Katz A, Gadd M, et al: Accelerated partial-breast irradiation using proton beams: initial clinical experience. *Int J Radiat Oncol Biol Phys* 2006, **66**(3):691–698.
52. Bush DA, Slater JD, Garberoglio C, Yuh G, Hocko JM, Slater JM: A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. *Cancer J* 2007, **13**(2):114–118.
53. Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM: Partial breast irradiation delivered with proton beam: results of a phase II trial. *Clin Breast Cancer* 2011, **11**(4):241–245. Epub 2011 Jun 12.
54. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. *Lancet* 1999, **353**(9149):267–272.
55. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. *Int J Radiat Oncol Biol Phys* 2000, **48**(3):635–642.
56. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. *J Clin Oncol* 2000, **18**(23):3904–3911.
57. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol* 2006, **24**(13):1990–1996.
58. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. *J Urol* 2006, **176**(4 Pt 1):1415–1419.
59. Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al: Proton therapy for prostate cancer: the initial Loma Linda University experience. *Int J Radiat Oncol Biol Phys* 2004, **59**(2):348–352.
60. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *JAMA* 2005, **294**(10):1233–1239. Erratum in: *JAMA*. 2008 Feb 27;299[8]:899–900.
61. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, et al: Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. *JAMA* 2010, **303**(11):1046–1053. Erratum in: *JAMA*. 2010 Apr 7;303[13]:1257.
62. Konski A, Speier W, Hanlon A, Beck JR, Pollack A: Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? *J Clin Oncol* 2007, **25**(24):3603–3608.
63. King CR, Brooks JD, Gill H, Presti JC Jr: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2012, **82**(2):877–882. Epub 2011 Feb 6.
64. Van de Water TA, Lomax AJ, Bijl HP, De Jong ME, Schilstra C, Hug EB, et al: Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. *Int J Radiat Oncol Biol Phys* 2011, **79**(4):1216–1224. Epub 2010 Aug 21.
65. Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, et al: Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. *Int J Radiat Oncol Biol Phys* 2005, **62**(2):494–500.
66. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, et al: Neuroendocrine tumors of the sinonasal tract: results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. *Cancer* 2002, **94**(10):2623–2634.
67. Truong MT, Kamat UR, Liebsch NJ, Curry WT, Lin DT, Barker FG 2nd, et al: Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. *Head Neck* 2009, **31**(10):1297–1308.
68. Lee UJ, Koom WS, Lee CG, Kim YB, Yoo SW, Keum KC, et al: Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. *Int J Radiat Oncol Biol Phys* 2009, **75**(4):1084–1091. Epub 2009 Mar 26.
69. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A: Radiotherapy dose-volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys* 2010, **76**(3 Suppl):S58–S63.
70. Luce BR, Brown RE: The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. *Int J Technol Assess Health Care* 1995, **11**(1):79–92.

doi:10.1186/1748-717X-7-174

Cite this article as: Foote et al.: The clinical case for proton beam therapy. *Radiation Oncology* 2012 **7**:174.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

